Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “Sanofi”

Description of Characteristics, Such as Age, Previous and Concurrent Treatments, Associated Diseases, of Patients With Asthma Treated With Dupilumab (DUPIXENT)Completed
NCT04550962N/AUpdated Jul 20, 2026
Sponsor: Sanofi
Asthma
Argentina, Chile, Colombia, Israel, Kuwait +7 more
Olfactory Cleft Obstruction and Electrophysiological Field Potentials Predict Olfactory Restoration by Dupilumab in CRSwNP Patients.Recruiting
NCT06892704N/AUpdated Jul 16, 2026
Sponsor: Northwestern University
Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP) · Smell Loss
United States
A Safety and Efficacy Study of One-time SAR402663 in Adults With Neovascular Age-related Macular DegenerationActive Not Recruiting
NCT06660667Phase 1, Phase 2Updated Jul 16, 2026
Sponsor: Sanofi
Neovascular Age-related Macular Degeneration
United States, United Kingdom
Isa-KRd vs KRd in Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation (IsKia TRIAL)Active Not Recruiting
NCT04483739Phase 3Updated Jul 16, 2026
Sponsor: European Myeloma Network B.V.
Multiple Myeloma
Belgium, Czechia, Germany, Greece, Italy +3 more
Isatuximab as Upfront Therapy for the Treatment of High Risk AL AmyloidosisActive Not Recruiting
NCT04754945Phase 1Updated Jul 14, 2026
Sponsor: Emory University
AL Amyloidosis
United States
Study Assessing Long-teRm Outcomes of dupiluMAb (DUPIXENT®) Treatment in Adult Patients With Chronic Rhinosinusitis With Nasal Polyposis (CRSwNP)Active Not Recruiting
NCT04959448N/AUpdated Jul 13, 2026
Sponsor: Regeneron Pharmaceuticals
Chronic Rhinosinusitis With Nasal Polyposis
United States, Canada, Germany, Italy, Japan +1 more
Proof of Concept Study of Rilzabrutinib in Adult Patients With Moderate-to-severe Atopic DermatitisCompleted
NCT05018806Phase 2Updated Jul 13, 2026
Sponsor: Sanofi
Atopic Dermatitis
United States, Canada, Chile, Czechia, Germany +2 more
Study to Evaluate the Efficacy and Safety of Venglustat in Adult and Pediatric Patients With Gaucher Disease Type 3Active Not Recruiting
NCT05222906Phase 3Updated Jul 13, 2026
Sponsor: Sanofi
Gaucher's Disease Type III
United States, Argentina, Canada, China, France +6 more
Actual Use Trial of Tadalafil 5 mgCompleted
NCT06805513Phase 3Updated Jul 13, 2026
Sponsor: Sanofi
Erectile Dysfunction
United States
Long-term Safety and Efficacy Study of Riliprubart in Participants With CIDPEnrolling By Invitation
NCT06859099Phase 3Updated Jul 13, 2026
Sponsor: Sanofi
Polyneuropathy, Inflammatory Demyelinating, Chronic
United States, Argentina, Brazil, Canada, Chile +16 more
Validation of Chlamydia Diagnostic Codes in TriNetX US EHR DataRecruiting
NCT07094373N/AUpdated Jul 10, 2026
Sponsor: Sanofi
Chlamydial Infections
United States
A Study to Investigate Safety and Efficacy of iGlarLixi in Adult Patients With Type 2 Diabetes MellitusCompleted
NCT06716424Phase 4Updated Jul 10, 2026
Sponsor: Sanofi
Type 2 Diabetes
India
A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic DermatitisActive Not Recruiting
NCT06407934Phase 3Updated Jul 10, 2026
Sponsor: Sanofi
Dermatitis Atopic
United States, Argentina, Australia, Brazil, Bulgaria +22 more
Venglustat in Combination With Cerezyme in Adult Patients With Gaucher Disease Type 3 With Venglustat Monotherapy ExtensionActive Not Recruiting
NCT02843035Phase 2Updated Jul 10, 2026
Sponsor: Genzyme, a Sanofi Company
Gaucher Disease Type 1 · Gaucher Disease Type 3
United States, Germany, Japan, United Kingdom
Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Participants With Mild AcneRecruiting
NCT07013747Phase 1, Phase 2Updated Jul 9, 2026
Sponsor: Sanofi Pasteur, a Sanofi Company
Acne
United States
Phase II Biomarker Study of BND-22 in Combination With Cemiplimab in Solid TumorsRecruiting
NCT06651593Phase 2Updated Jul 9, 2026
Sponsor: M.D. Anderson Cancer Center
Solid Tumors
United States
TG-INSIGHT With Joint POCUS, Hemostatic Potential in Patients With Severe Hemophilia A on Novel Replacement and Substitution FVIII TherapiesNot Yet Recruiting
NCT07692217N/AUpdated Jul 9, 2026
Sponsor: University of Texas Southwestern Medical Center
Hemophilia A · Factor VIII (FVIII)
United States
Efficacy and Safety of iGlarLixi Versus Standard of Care in a Real-world Adult China Population With Uncontrolled Type 2 Diabetes on Oral AgentsRecruiting
NCT07307235Phase 4Updated Jul 7, 2026
Sponsor: Shanghai Zhongshan Hospital
Type 2 Diabetes
China
A Study to Investigate the Efficacy and Safety of Rilzabrutinib in Adult Participants With Graves' DiseaseRecruiting
NCT06984627Phase 2Updated Jul 7, 2026
Sponsor: Sanofi
Graves' Disease
Canada, Germany, Italy, Spain, United Kingdom
Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC)Recruiting
NCT05263206Phase 3Updated Jul 6, 2026
Sponsor: Sanofi
Pruritus
United States, Argentina, Canada, China, France +8 more
First-in-human Study of SAR443579 Infusion in Male and Female Children and Adult Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), High Risk-myelodysplasia (HR-MDS), or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)Terminated
NCT05086315Phase 1, Phase 2Updated Jul 6, 2026
Sponsor: Sanofi
Acute Lymphocytic Leukaemia · Acute Myeloid Leukaemia Refractory · Myelodysplastic Syndromes · Blastic Plasmacytoid Dendritic Cell Neoplasia
United States, Australia, China, France, Netherlands
Evaluation of Biomarkers of Atopic Dermatitis in Pediatric Patients (PEDISTAD BIOMARKER STUDY)Completed
NCT03849716N/AUpdated Jul 6, 2026
Sponsor: Sanofi
Dermatitis Atopic
United States, Argentina, Australia, Brazil, Canada +4 more
LATE-ONSET POMPE DISEASE AND CEREBROVASCULAR MANIFESTATIONSCompleted
NCT07685314N/AUpdated Jul 6, 2026
Sponsor: Hospitales Universitarios Virgen del Rocío
Late-Onset Pompe Disease
Spain
Isatuximab, Carfilzomib, and Pomalidomide for the Treatment of Relapsed or Refractory Multiple MyelomaActive Not Recruiting
NCT04850599Phase 2Updated Jul 2, 2026
Sponsor: OHSU Knight Cancer Institute
Recurrent Plasma Cell Myeloma · Refractory Plasma Cell Myeloma
United States
A Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injections Compared With Placebo in Male and Female Participants Aged at Least 18 Years (STYLE 1)Active Not Recruiting
NCT06687967Phase 3Updated Jul 2, 2026
Sponsor: Sanofi
Lichen Simplex Chronicus
United States, Argentina, Canada, Chile, China +12 more

Previous page Next page